← Back to Search

Texting Intervention for Gestational Diabetes

N/A

Waitlist Available

Research Sponsored by St. Louis University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

The patient has been diagnosed with gestational diabetes or is a patient with known diabetes and a confirmed viable pregnancy

The patient is a pregnant female 18 years of age or older

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 12 months

Awards & highlights

Study Summary

This trial will test whether or not a text message reminder and education system will help patients with diabetes in pregnancy better adhere to their care regimen.

Who is the study for?

This trial is for pregnant women aged 18 or older with either gestational diabetes or pre-existing diabetes and a confirmed viable single pregnancy. They must have access to a cell phone with texting capabilities. Women hospitalized for pregnancy complications or without a cell phone, as well as those carrying babies with malformations, cannot participate.Check my eligibility

What is being tested?

The study is testing whether text message reminders and educational content can help pregnant women with diabetes better adhere to their care regimen. Participants will be randomly assigned to receive these text interventions and their adherence to the recommended care will be monitored.See study design

What are the potential side effects?

Since this trial involves sending text messages rather than medical treatments, there are no direct physical side effects expected from participating in this study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have diabetes and am currently pregnant.

Select...

I am a pregnant woman aged 18 or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

compliant diabetes care

Trial Design

2Treatment groups

Active Control

Group I: TextingActive Control1 Intervention

Patients in the "Texting" group will receive reminders based on their individual disease treatment. A text message shall be sent one day (12 to 36 hours) before appointments to remind about the appointment and with instructions to bring glucose and food records to the appointment. If medication changes are made at the appointment, the patient will receive a text message reminder the day after her appointment to reinforce the regimen. Postpartum patients who had GDM will receive a text message reminder to complete their glucose tolerance test. A reminder will be sent at 2 weeks postpartum followed by a reminder at 6 weeks and 10 weeks postpartum if the testing is not completed.

Group II: No textingActive Control1 Intervention

Patients in the contact control group will be enrolled in the text4baby program with assistance from a healthcare provider. As the study will conclude upon the patient's postpartum visit, she will be offered the option of discontinuing messages, which otherwise would continue through the infant's first year of life.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

St. Louis UniversityLead Sponsor

194 Previous Clinical Trials

43,470 Total Patients Enrolled

2 Trials studying Diabetes

307 Patients Enrolled for Diabetes

Dorothea Mostello, MDStudy Chair - St. Louis University

All Saints Special Care Hospital, Anderson Hospital, HSHS St. Joseph's Hospital Breese, SSM DePaul Health Center, SSM St. Mary's Health Center, Southeast Hospital, St. Louis University Hospital

Johns Hopkins University School Of Medicine (Medical School)

University Co Hlth Sci Center (Residency)

2 Previous Clinical Trials

270 Total Patients Enrolled

Media Library

Texting Clinical Trial Eligibility Overview. Trial Name: NCT03025984 — N/A

Diabetes Research Study Groups: Texting, No texting

Diabetes Clinical Trial 2023: Texting Highlights & Side Effects. Trial Name: NCT03025984 — N/A

Texting 2023 Treatment Timeline for Medical Study. Trial Name: NCT03025984 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this investigation accommodate elderly participants?

"This study is available to patients aged 18 to 55, while there are separate trials for those younger or older. Specifically, 184 studies focus on the paediatric demographic and 875 address geriatric subjects."

Answered by AI

Is there scope for enrollment in this scientific experiment?

"Accessing the clinicaltrials.gov page reveals that this particular study, originally posted on December 1st 2016 and recently updated November 11th 2022, is not recruiting patients at present. However, there are presently 1,170 other medical trials actively seeking to enrol candidates."

Answered by AI

What criteria should be met in order to qualify for this research endeavor?

"This clinical trial is admitting 185 individuals with diabetes mellitus ranging between 18 and 55 years old. To be eligible, the patient should meet certain requirements: they must be a pregnant female over the age of eighteen; have been diagnosed with gestational or pre-existing diabetes; possess a viable singleton pregnancy; and own a cellular phone with an active text messaging plan."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Texting for Diabetes

Dorothea Mostello, MD 2016. "Texting for Diabetes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03025984.